NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Talphera, Inc. TLPH
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$28,000
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-114.2%
Net margin · FY25
-51035.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 28,000.00
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 51036 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-114.2%
Return on equity, FY2025
ROE
Operating margin-48157.1%
Net margin-51035.7%
Return on assets-59.6%
Each USD of equity lost 114 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−65.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−65.1%
−48.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+37.4%
Change, 10 years—
The share count grew 37% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 29.7M
total assets, end of FY2025
Total assetsUSD 29.7M
EquityUSD 17.0M
CashUSD 5.9M
Current ratio5.49×
Equity funds 57% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
−1.29
5.72
−5.86
−0.47
−0.67
−0.81
−1.10
−0.95
−0.60
−0.91
−0.59
−1.51
−1.16
−21.84
−34.93
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−114.2
−117.7
−102.4
·
·
·
·
·
·
−310.8
−61.2
−55.7
−43.8
−130.0
·
·
·
·
·
Shares out B
0.05
0.02
0.02
0.01
0.01
0.10
0.08
0.08
0.05
0.05
0.05
0.04
0.04
0.04
0.02
0.00
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed